最新公告列表 《迈得医疗工业设备股份有限公司2026年第一次临时股东会会议资料》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月29日收盘，迈得医疗（688310）报收于16.04元，较前一交易日下跌2.08%，最新总市值 为26.66亿元。该股当日开盘16.6元，最高16.89元，最低15.99元，成交额达9773.29万元，换手率为 3.59%。 近日，迈得医疗工业设备股份有限公司披露《2026年第一次临时股东会会议资料》，拟向控股子公司浙 江迈得顺隐形眼镜有限公司提供总额不超过人民币1亿元的财务资助，资助期限为自股东会审议通过之 日起3年内，借款利率参照一年期LPR，利息按实际借款占用天数计算。迈得顺可循环使用额度。公司 实际控制人林军华、持股5%以上股东陈万顺为本次资助提供连带责任保证。本次资助事项构成关联交 易，不构成重大资产重组。董事会已提请股东会授权管理层办理相关协议签署及款项支付等事宜。 ...

证券代码：688310 证券简称：迈得医疗 迈得医疗工业设备股份有限公司 2026 年第一次临时股东会会议资料 二〇二六年一月 1 | 2026 年第一次临时股东会会议须知 3 | | --- | | 2026 年第一次临时股东会会议议程 6 | | 2026 年第一次临时股东会会议议案 8 | | 议案一：关于向控股子公司提供财务资助暨关联交易的议案 8 | 迈得医疗工业设备股份有限公司 2026 年第一次临时股东会会议资料 迈得医疗工业设备股份有限公司 2026 年第一次临时股东会会议须知 为维护全体股东的合法权益，确保股东会会议秩序和议事效率，保证股东会 的顺利召开，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司股东会规则》以及《迈得医疗工业设备股份有限公司章程》《迈得医疗工业 设备股份有限公司股东会议事规则》等相关规定，特制定本会议须知： 一、公司负责本次股东会的议程安排和会务工作，为确认出席会议的股东或 其代理人或其他出席者的出席资格，会议工作人员将对出席会议者的身份进行必 要的核对工作，请被核对者给予配合。 二、为保证本次会议的严肃性和正常秩序，切实维护股东的合法权益，出席 会议 ...

Policy Developments - The National Health Commission released the "Guidelines for Clinical Application of New Antitumor Drugs (2025 Edition)" to standardize the clinical use of new antitumor drugs, which include small molecule targeted drugs and monoclonal antibodies [2] Drug and Device Approvals - North China Pharmaceutical announced it received a drug registration certificate for Tacrolimus capsules (0.5mg, 1mg), which is an immunosuppressant used to prevent organ transplant rejection [4] - A new lung cancer early diagnosis kit developed by the Hangzhou Institute of Medicine has been approved for market release, potentially improving early diagnosis rates for lung cancer [5] Financial Reports - YaoXingTang projected a net profit of 260 million to 330 million yuan for 2025, representing a year-on-year increase of 127.79% to 189.12%, driven by improved operational efficiency and resource allocation [7] - MaiDe Medical expects a revenue of approximately 447 million yuan for 2025, marking a year-on-year increase of about 62.81%, and anticipates a net profit of around 66.52 million yuan, indicating a turnaround from previous losses [8] Capital Market Activities - Tongrentang Medical submitted an IPO application to the Hong Kong Stock Exchange, with CICC as the sponsor [10] - New Jingzhiyuan Biotech completed over 200 million yuan in Series B financing, led by Xingze Capital and a well-known industry fund [11] Industry Developments - Over 40% of county-level traditional Chinese medicine hospitals have initiated the establishment of county medical communities, with a total of 3,099 such communities formed across 2,199 counties and cities [13] - The National Health Commission reported that all tertiary public traditional Chinese medicine hospitals have achieved full coverage in pediatrics, enhancing health services for children and the elderly [14]

Core Viewpoint - The company, Maide Medical Industrial Equipment Co., Ltd., anticipates significant growth in revenue and profitability for the year 2025, marking a turnaround from previous losses [2][9]. Group 1: Performance Forecast - The company expects to achieve an operating revenue of approximately 447.50 million yuan for 2025, representing an increase of about 172.65 million yuan, or 62.81% year-on-year [2]. - The net profit attributable to the parent company is projected to be around 66.52 million yuan, indicating a turnaround from a loss in the previous year [2]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is estimated at approximately 54.64 million yuan [3]. Group 2: Previous Year Performance - In the previous year, the total profit was reported at -29.23 million yuan [5]. - The net profit attributable to the parent company was -19.98 million yuan [6]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, was -26.28 million yuan [7]. - The basic earnings per share for the previous year were -0.12 yuan [8]. Group 3: Reasons for Performance Change - The anticipated revenue growth is attributed to the company's effective production planning and delivery, alongside a focus on technological innovation and process iteration [9]. - The blood purification and medical device combination equipment sectors are performing well, particularly due to strong demand for medical consumables in the end market [9]. - The company is concentrating on research and market development for new products in the medical device combination equipment sector, which is expected to drive significant revenue growth [9].

Core Viewpoint - The company, Maide Medical, has released its 2025 annual performance forecast, indicating significant revenue growth and a return to profitability, primarily driven by increased sales in smart medical equipment [1]. Group 1: Financial Performance - As of January 26, 2026, Maide Medical's stock closed at 16.26 yuan, down 1.57% from the previous trading day, with a total market capitalization of 2.703 billion yuan [1]. - The company expects to achieve approximately 447.50 million yuan in revenue for 2025, representing a year-on-year growth of 62.81% [1]. - The net profit attributable to the parent company is projected to be around 66.52 million yuan, marking a return to profitability [1]. - The net profit after deducting non-recurring gains and losses is estimated to be about 54.64 million yuan [1]. Group 2: Revenue Drivers - The significant growth in revenue is primarily attributed to a substantial increase in sales of smart medical equipment, particularly in the drug and device combination sector [1].

Group 1 - The core viewpoint of the news is that Maide Medical (688310) has released its performance forecast for 2025, indicating significant revenue growth and a return to profitability [1][3] Group 2 - On January 26, Maide Medical's stock closed at 16.26 yuan, down 1.57%, with a turnover rate of 1.94% and a trading volume of 32,300 shares, amounting to a transaction value of 52.25 million yuan [1] - The company expects a total operating revenue of approximately 447.50 million yuan for the year 2025, representing a year-on-year increase of 62.81% [1][3] - The forecasted net profit attributable to the parent company is around 66.52 million yuan, indicating a turnaround from previous losses [1][3] - The net profit after deducting non-recurring gains and losses is estimated to be approximately 54.64 million yuan, also reflecting a return to profitability [1][3] - The growth in performance is primarily attributed to a significant increase in revenue from the combination of pharmaceutical and medical equipment intelligent devices [1]

Core Viewpoint - The company Maide Medical (688310) expects a significant turnaround in its financial performance for the year 2025, projecting a net profit of 66.52 million yuan compared to a loss of 19.98 million yuan in the previous year [4]. Financial Performance - The projected net profit for 2025 is 66.52 million yuan, while the expected non-recurring net profit is 54.64 million yuan, showing substantial improvement from losses of 19.98 million yuan and 26.28 million yuan, respectively, in the previous year [4]. - The company's price-to-earnings (P/E) ratio is approximately 40.63 times, the price-to-book (P/B) ratio is about 3.35 times, and the price-to-sales (P/S) ratio is around 9.66 times based on the closing price on January 26 [4]. Revenue Growth - The company anticipates significant revenue growth in 2025, driven by effective production planning and a focus on technological innovation and process iteration, which enhance product competitiveness and market influence [13]. - The blood purification and drug-device combination intelligent equipment business segments are performing well, particularly due to strong demand growth in the terminal market for medical consumables [13]. Historical Financial Trends - Historical data indicates a trend of increasing net profit and non-recurring net profit, with the company projecting a recovery in profitability for 2025 after previous losses [14]. - The year-on-year growth rates for net profit and non-recurring net profit are expected to show significant improvement, reflecting the company's recovery trajectory [14].

Group 1 - Evert plans to acquire equity in Shengpu Co., with stock suspension starting January 27, 2026, expected to last no more than 10 trading days [5] - Haike New Source signed a long-term cooperation agreement with BYD Lithium Battery to supply at least 100,000 tons of electrolyte solvent annually for three years [5] - Sanxiang Bio has developed a CE-certified Nipah virus nucleic acid testing kit and a domestic research version, responding to the Nipah virus outbreak in India [9][10] Group 2 - Sangfor Health expects a Q4 net profit of approximately 2.5 billion yuan, a 1097% increase from the previous quarter, driven by a significant payment from Pfizer for the 707 project [2] - Puran Co. anticipates a Q4 net profit of about 1.46 billion yuan, a 696% increase from Q3, despite an annual decrease of approximately 29.89% [3][4] - Chip Source Micro expects a net profit of 52 million to 76 million yuan for 2025, a decrease of 62.53% to 74.36% year-on-year due to increased costs and reduced other income [6] Group 3 - Maide Medical forecasts a net profit of approximately 66.5 million yuan for 2025, marking a turnaround from losses in the previous year [7] - Ruixin Micro expects a net profit of 1.023 billion to 1.103 billion yuan for 2025, representing a growth of 71.97% to 85.42% year-on-year [8] - Qingda Environmental anticipates a net profit of 165 million to 190 million yuan for 2025, an increase of 77.47% to 104.36% year-on-year [10] Group 4 - Jiangxun Technology expects a net profit increase of approximately 86.44% for 2025, reaching around 156 million yuan [11] - Micron Bio anticipates a net profit of approximately 53.5 million yuan for 2025, achieving profitability after previous losses [11] - Blue Special Optics forecasts a net profit of 375 million to 400 million yuan for 2025, a growth of 70.04% to 81.38% year-on-year [13]

Core Viewpoint - The company expects a significant increase in net profit for the year 2025, projecting approximately 66.52 million yuan, driven by substantial growth in overall operating revenue and successful product delivery [1] Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of approximately 66.52 million yuan for the year 2025 [1] - The increase in revenue is attributed to the orderly implementation of production plans and a focus on technological innovation and process iteration [1] - The blood purification and drug-device combination intelligent equipment business is performing well, particularly due to strong demand growth in the terminal market for medical consumables [1] Group 2: Q3 Financial Results - For the first three quarters of 2025, the company's main revenue reached 225 million yuan, a year-on-year increase of 2.31% [2] - The net profit attributable to shareholders for the same period was 8.84 million yuan, reflecting a year-on-year increase of 15.82% [2] - In Q3 2025 alone, the company reported a main revenue of 83.64 million yuan, a significant year-on-year increase of 54.38% [2] - The net profit for Q3 2025 was 2.79 million yuan, showing a remarkable year-on-year increase of 224.07% [2] - The company reported a debt ratio of 29.86% and a gross profit margin of 40.19% [2]

Core Viewpoint - The company expects a significant increase in net profit for the year 2025, projecting a profit of approximately 54.64 million yuan after excluding non-recurring gains and losses, driven by substantial growth in overall operating revenue and effective product delivery [1] Group 1: Performance Forecast - For the year 2025, the company anticipates a net profit of about 54.64 million yuan after excluding non-recurring gains and losses [1] - The increase in revenue is attributed to the orderly implementation of production plans and a focus on technological innovation and process iteration [1] - The blood purification and medical device combination intelligent equipment businesses are performing well, particularly due to strong demand growth in the terminal market for medical consumables [1] Group 2: Q3 Financial Results - In the first three quarters of 2025, the company's main revenue reached 225 million yuan, a year-on-year increase of 2.31% [2] - The net profit attributable to the parent company was 8.84 million yuan, up 15.82% year-on-year [2] - The third quarter alone saw a main revenue of 83.64 million yuan, representing a 54.38% year-on-year increase, with a net profit of 2.79 million yuan, up 224.07% year-on-year [2] - The company reported a gross margin of 40.19% and a debt ratio of 29.86% [2]